Chengdu-based biotech company Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for HP518, a Category 1 chemical drug intended to treat metastatic castration-resistant prostate cancer (mCRPC).
HP518: A Promising PROTAC Drug for Prostate Cancer
HP518 is an androgen receptor (AR) targeted proteolysis-targeting chimeric (PROTAC) drug that is currently undergoing clinical trials. This innovative drug is designed to address the complex challenges of mCRPC, offering a potential new treatment option for patients. The drug has also been filed for clinical trials in the United States, indicating Hinova Pharmaceuticals’ commitment to making this treatment available globally.-Fineline Info & Tech
